Volume 20 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(5): 796-800
LI Cheng-wei, QIAO Meng-xiang, LIU Tie-cheng, JIN Gong-sheng. Effect of preoperative total cholesterol and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer[J]. Chinese Journal of General Practice, 2022, 20(5): 796-800. doi: 10.16766/j.cnki.issn.1674-4152.002457
Citation: LI Cheng-wei, QIAO Meng-xiang, LIU Tie-cheng, JIN Gong-sheng. Effect of preoperative total cholesterol and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer[J]. Chinese Journal of General Practice, 2022, 20(5): 796-800. doi: 10.16766/j.cnki.issn.1674-4152.002457
shu

Effect of preoperative total cholesterol and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer

doi: 10.16766/j.cnki.issn.1674-4152.002457

  • Department of Oncology Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0352

  • Received Date: 2021-09-15
    Available Online: 2022-09-05
    Abstract
  •   Objective  To determine serum total cholesterol (TC) and high-density lipoprotein-cholesterol (HDL-C) of patients with breast cancer, explore the effect of preoperative blood lipid levels on the prognosis of patients with breast cancer.  Methods  Fasting plasma lipid in the morning and clinical pathological data of 341 patients with breast cancer confirmed by pathology from January 2012 to December 2014 in the First Affiliated Hospital of Bengbu Medical College were collected retrospectively. Kaplan-Meier analysis and Cox proportional hazard regression model were used to analyse overall survival (OS) and disease-free survival (DFS).  Results  The average OS of patients with TC < 6.2 mmol/L was 96.2 months, whereas that of patients with TC≥6.2 mmol/L was 95.4 months (P=0.556). The average DFS of patients with TC < 6.2 mmol/L was 95.9 months, and that of patients with TC≥6.2 mmol/L was 94.0 months (P=0.122). In different levels of TC groups, the OS rate and DFS rate were not statistically significant. The average OS of patients with HDL-C < 1.04 mmol/L was 94.7 months, whereas that of patients with HDL-C≥1.04 mmol/L was 97.6 months (P=0.019). The average DFS of patients with HDL-C < 1.04 mmol/L was 93.2 months, whereas the average DFS of patients with HDL-C level≥1.04 mmol/L was 94.7 months (P=0.003). In different levels of HDL-C groups, the OS time and DFS time were statistically significant. COX multivariate analysis showed that high HDL-C was beneficial to DFS (HR=3.916, 95% CI: 1.355-11.313, P=0.012).  Conclusion  The preoperative HDL-C level may be an independent factor predicting DFS in patients with breast cancer.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
    [2]
    SUN Y S, ZHAO Z, YANG Z N, et al. Risk factors and preventions of breast cancer[J]. Int J Biol Med Sci, 2017, 13(11): 1387. doi: 10.7150/ijbs.21635
    [3]
    KABAT G C, KIM M Y, CHLEBOWSKI R T, et al. Serum lipids and risk of obesity-related cancers in postmenopausal women[J]. Cancer Causes Control, 2018, 29(1): 13-24. doi: 10.1007/s10552-017-0991-y
    [4]
    NELSON E R. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer[J]. Mol Cell Endocrinol, 2018, 466: 73-80. doi: 10.1016/j.mce.2017.09.021
    [5]
    邓赢芳, 王淼舟. 血脂水平与乳腺癌关系的研究现状和进展[J]. 临床医药文献电子杂志, 2019, 6(5): 1. doi: 10.3877/j.issn.2095-8242.2019.05.001

    DENG Y F, WANG M Z. Research status and progress of the relationship between blood lipid level and breast cancer[J]. Journal of Clinical Medical Literature (ElectronicEdition), 2019, 6(5): 1. doi: 10.3877/j.issn.2095-8242.2019.05.001
    [6]
    MAZZUFERI G, BACCHETTI T, ISLAM M O, et al. High density lipoproteins and oxidative stress in breast cancer[J]. Lipids Health Dis, 2021, 20(1): 1-13. doi: 10.1186/s12944-020-01429-x
    [7]
    TRYGVE L, MORTENSEN E S, HAWA N, et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes[J]. Bmc Cancer, 2018, 18(1): 1-11. doi: 10.1186/s12885-017-3892-2
    [8]
    中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202110015.htm

    Breast Cancer Committee of Chinese Anti-Cancer Association. Chinese Anti-Cancer Association Guidelines and Specifications for Diagnosis and Treatment of Breast Cancer (2021 edition)[J]. China Oncology, 2021, 31(10): 954-1040. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202110015.htm
    [9]
    中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华健康管理学杂志, 2017, 11(1): 7-28. doi: 10.3760/j.issn.1674-0815.2017.01.003

    Joint Committee on the Revision of Guidelines for Prevention and Treatment of dyslipidemia in Adults in China. 2016 Chinese guideline for the management of dyslipidemia in adults[J]. Chinese Journal of Health Management, 2017, 11(1): 7-28. doi: 10.3760/j.issn.1674-0815.2017.01.003
    [10]
    潘婉婉, 董孟浩, 余发智, 等. 外周血炎症指标NLR、PLR、LMR预测乳腺癌新辅助化疗疗效的价值[J]. 中华全科医学, 2021, 19(9): 1442-1446. doi: 10.16766/j.cnki.issn.1674-4152.002081

    PAN W W, DONG M H, YU F Z, et al. Value of peripheral inflammatory markers NLR, PLR and LMR in predicting the efficacy of neoadjuvant chemotherapy for breast cancer[J]. Chinese general practice, 2021, 19(9): 1442-1446. doi: 10.16766/j.cnki.issn.1674-4152.002081
    [11]
    NOWAK C, ǍRNLÖV J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk[J]. Nat Commun, 2018, 9(1): 1-7. doi: 10.1038/s41467-017-02088-w
    [12]
    WANG Y Y, ATTANÉ C, MILHAS D, et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells[J]. JCI Insight, 2017, 2(4): e87489. DOI: 10.1172/jci.insight.87489.
    [13]
    张艳利, 陈茂山, 杨光伦. 血清血脂和脂蛋白水平与乳腺癌发生及其临床病理学特征的相关性分析[J]. 中国普外基础与临床杂志, 2018, 25(2): 171-177. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201802009.htm

    ZHANG Y L, CHEN M S, YANG G L. Association analysis of serum lipids and lipoprotein levels with the occurrence of breast cancer and clinicopathological characteristics of breast cancer patients[J]. Chinese Journal of Bases and Clinics in General Surgery, 2018, 25(2): 171-177. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201802009.htm
    [14]
    CHIMENTO A, CASABURI I, AVENA P, et al. Cholesterol and its metabolites in tumor growth: Therapeutic potential of statins in cancer treatment[J]. Front Endocrinol, 2019, 9: 807. doi: 10.3389/fendo.2018.00807
    [15]
    MUNIR M T, PONCE C, POWELL C A, et al. The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer[J]. J Steroid Biochem Mol Biol, 2018, 183: 1-9. doi: 10.1016/j.jsbmb.2018.05.001
    [16]
    WU J, LEI X, PAN X, et al. Association between serum lipids and breast cancer risk in premenopausal women: Systematic review and meta-analysis[J]. J Int Med Res, 2021, 49(11). DOI: 10.1177/03000605211061033.
    [17]
    GUAITA-ESTERUELAS S, GUMA J, MASANA L, et al. The peritumoural adipose tissue microenvironment and cancer. The roles of fatty acid binding protein 4 and fatty acid binding protein 5[J]. Mol Cell Endocrinol, 2018, 462: 107-118. doi: 10.1016/j.mce.2017.02.002
    [18]
    SHEIKHPOUR E, NOORBAKHSH P, FOROUGHI E, et al. A survey on the role of interleukin-10 in breast cancer: A narrative[J]. Rep Biochem Mol Biol, 2018, 7(1): 30-37.
    [19]
    黄赞. 脂质代谢, 体质量指数与乳腺癌发生的关系[J]. 中国实用医药, 2019, 14(27): 3-5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201927002.htm

    HUANG Z. Correlation of lipid metabolism, body mass index and breast cancer[J]. Practical medicine in China, 2019, 14(27): 3-5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201927002.htm
    [20]
    OZMEN H K, ERDEMCI B, ASKIN S, et al. Carnitine and adiponectin levels in breast cancer after radiotherapy[J]. Open Med, 2017, 12: 189-194. doi: 10.1515/med-2017-0028
    [21]
    于子棋, 肖志, 邬玉辉, 等. 乳腺癌患者化疗前后血脂血糖及体质量指数的变化[J]. 中国普通外科杂志, 2017, 26(11): 1502-1505. doi: 10.3978/j.issn.1005-6947.2017.11.022

    YU Z Q, XIAO Z, WU Y H, et al. Changes of blood lipid, blood glucose and body mass index in breast cancer patients before and after chemotherapy[J]. Chinese Journal of General Surgery, 2017, 26(11): 1502-1505. doi: 10.3978/j.issn.1005-6947.2017.11.022
    [22]
    ALOMAR S A, GǍMAN M A, PRABAHAR K, et al. The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials[J]. Exp Gerontol, 2022, 159: 111680. DOI: 10.1016/j.exger.2021.111680.
    [23]
    李江涛. 研究阿那曲唑对乳腺癌术后化疗患者血脂、肝功能的影响[J]. 北方药学, 2018, 15(6): 29. https://www.cnki.com.cn/Article/CJFDTOTAL-BFYX201806020.htm

    LI J T. To study the effect of anastrozole on blood lipid and liver function in patients with breast cancer undergoing postoperative chemotherapy[J]. Journal of North Pharmacy, 2018, 15(6): 29. https://www.cnki.com.cn/Article/CJFDTOTAL-BFYX201806020.htm
    [24]
    JI Y L, ROUNDS T, CROCKER A, et al. The effect of atorvastatin on breast cancer biomarkers in high-risk women[J]. Cancer Prev Res, 2016, 9(5): 379-384. doi: 10.1158/1940-6207.CAPR-15-0300
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (345) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return